CURRENT ENTERPRISE WORK · RAPHAEL PHARMACEUTICAL
A filed AI transformation and growth engagement.
The public record describes a managed-services relationship between Raphael Pharmaceutical and AIcreatesAI, presented here with its material limitations intact.
WHAT THE FILING SAYS
Managed AI transformation, commercialization, communications, product and growth operations.
Raphael Pharmaceutical’s SEC-filed agreement states that AIcreatesAI will serve as its managed partner across those areas for an initial 12-month term, subject to Raphael’s approval, applicable law and the agreement’s compliance controls.
View the SEC filingACCURACY NOTE
Contracted value is not cash received.
The agreement specifies an annual managed-services fee and monthly payment schedule, but also includes deferred-payment provisions when funds are temporarily unavailable. This public page does not claim that any amount has been collected.
The filing also states that the parties are independent contractors; it does not create a legal partnership, joint venture or equity partnership.
COMPANY CONTEXT
Raphael Pharmaceutical is a pharmaceutical research and development company.
Its corporate site describes work in cannabinoid-based formulas and research, including rheumatoid arthritis as its lead candidate area.